SAN FRANCISCO, Oct. 14 /PRNewswire/ -- Today it was announced that a new life sciences investment newsletter has launched and is available online via subscription. The Centient Biotech Investor(TM) newsletter, written by Frank H. Eeckman, M.D., Ph.D., and Greg Scott, both 20-year industry veterans, features highly readable biotech and pharmaceutical sector analysis and commentary on emerging trends and specific investment opportunities.
The Centient Biotech Investor provides investors in public and pre-IPO companies with critical information and insider knowledge about the biotech industry that cannot be found anywhere else. The editors are leveraging a thorough understanding of research science, clinical medicine and biotechnology business operations to enable all levels of investors to make better decisions about their life science portfolios. Both editors are involved in the day-to-day operations of biotechnology companies and their insider knowledge is equally applicable to both analysts and executives who closely follow the industry.
“The Centient Biotech Investor doesn’t aim to replicate the offerings of other news and financial sources but rather to deliver insight into the technologies and practices shaping the industry,” said Dr. Eeckman. “Our goal is to help both individual and institutional investors better understand the playing field and identify where the next big success or failure will be.”
The biotech sector is complex and volatile but since late 2000 it has played a key role in the rebound of the overall equities market. To allow investors to make informed decisions, the editors have developed the Centient Biotech 200(TM) Index to track the performance of the life science market as well as specific companies. This proprietary index incorporates a comprehensive list of biotech companies and the newsletter includes a weekly chart of the Index’s performance and tables showing each company’s week-over-week performance. The Centient Biotech Investor is the only source of in-depth analysis and thorough tracking for this broad list of over 200 companies.
The Centient Biotech Investor is available to subscribers online at: http://www.biotechinvestor.com/, and visitors may register for a two week no-risk free trial.
The Centient Biotech Investor’s managing editor, Frank H. Eeckman M.D., Ph.D. is a seasoned biotech executive and writes many of the articles and analyses. As a sought-after consultant to venture capitalists and other investment groups, Dr. Eeckman has analyzed hundreds of life science companies for potential investments. He has helped found three Silicon Valley biotechs and serves on the board of several others. Previously he was head of a discovery group at Parke-Davis/Pfizer and led the bioinformatics effort for the Human Genome Project at Lawrence Berkeley National Laboratory. He is currently the co-founder and Chief Scientific Officer of a biotechnology consulting company. Dr. Eeckman started his medical career as a neurologist and he holds a Ph.D. in Physiology from the University of California at Berkeley, where he was a Fulbright Scholar.
Executive editor Greg Scott provides the business and editorial direction for The Centient Biotech Investor. He is the CEO and founder of a consulting firm providing business strategy services to emerging and established biotechnology companies, a founding partner of an investment fund focused on biotech and med-tech companies, and co-founder of Life Science Angels, an early-stage investment group (http://www.lifescienceangels.com/). Previously Mr. Scott founded three high technology startups and held senior executive positions at EDS, MCI, and Price Waterhouse.
Through their day-to-day involvement with drug discovery and development companies, both Dr. Eeckman and Mr. Scott are in an unique position to understand the biotech industry, its drivers and critical success factors and interpret the impact of business and regulatory events for the benefit of their readers.
About The Centient Biotech Investor:
The Centient Biotech Investor is an online newsletter focused on delivering insight, commentary and investment recommendations on the biotechnology industry. Editors Frank H. Eeckman, M.D., Ph.D. and Greg Scott are industry insiders with firsthand operational knowledge of the sector and are producing this newsletter to share their knowledge with professional and individual investors and industry executives. In addition to articles and analysis, the newsletter tracks the Centient Biotech 200(TM), its proprietary index of key biotech stocks. The newsletter is available online to subscribers at: http://www.biotechinvestor.com/.
Company Contacts: The Centient Biotech Investor Greg Scott 858-755-9232 gscott@centient.com For The Centient Biotech Investor Jennifer Larson 415-409-2729 jlarson@labfive.com
Centient Biotech Investor
CONTACT: Greg Scott of The Centient Biotech Investor, +1-858-755-9232,or gscott@centient.com; or Jennifer Larson, +1-415-409-2729, orjlarson@labfive.com, for Centient Biotech Investor
Web site: http://www.biotechinvestor.com/